Par Drugs Gross Profit vs. Return On Asset
| PAR Stock | 288.35 4.15 1.42% |
Gross Profit | First Reported 2018-06-30 | Previous Quarter 151.2 M | Current Value 203.3 M | Quarterly Volatility 71.6 M |
For Par Drugs profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Par Drugs to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Par Drugs And utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Par Drugs's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Par Drugs And over time as well as its relative position and ranking within its peers.
Par |
Par Drugs And Return On Asset vs. Gross Profit Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Par Drugs's current stock value. Our valuation model uses many indicators to compare Par Drugs value to that of its competitors to determine the firm's financial worth. Par Drugs And is considered to be number one stock in gross profit category among its peers. It also is considered to be number one stock in return on asset category among its peers . The ratio of Gross Profit to Return On Asset for Par Drugs And is about 3,306,119,942 . At present, Par Drugs' Gross Profit is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Par Drugs' earnings, one of the primary drivers of an investment's value.Par Return On Asset vs. Gross Profit
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Par Drugs |
| = | 457.57 M |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Par Drugs |
| = | 0.14 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Par Return On Asset Comparison
Par Drugs is currently under evaluation in return on asset category among its peers.
Par Drugs Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Par Drugs, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Par Drugs will eventually generate negative long term returns. The profitability progress is the general direction of Par Drugs' change in net profit over the period of time. It can combine multiple indicators of Par Drugs, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 1.2 M | 1.3 M | |
| Operating Income | 551.6 M | 579.2 M | |
| Income Before Tax | 195.2 M | 204.9 M | |
| Total Other Income Expense Net | -356.4 M | -338.6 M | |
| Net Income | 145 M | 88.5 M | |
| Income Tax Expense | 50.2 M | 52.7 M | |
| Net Interest Income | -1.1 M | -1.1 M | |
| Interest Income | 826.9 K | 1.1 M | |
| Net Income From Continuing Ops | 145 M | 87 M | |
| Net Income Applicable To Common Shares | 106 M | 65.2 M | |
| Change To Netincome | 4.9 M | 5.6 M |
Par Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Par Drugs. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Par Drugs position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Par Drugs' important profitability drivers and their relationship over time.
Use Par Drugs in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Par Drugs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Par Drugs will appreciate offsetting losses from the drop in the long position's value.Par Drugs Pair Trading
Par Drugs And Pair Trading Analysis
The ability to find closely correlated positions to Par Drugs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Par Drugs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Par Drugs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Par Drugs And to buy it.
The correlation of Par Drugs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Par Drugs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Par Drugs And moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Par Drugs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Par Drugs position
In addition to having Par Drugs in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Marketing Thematic Idea Now
Marketing
Companies providing marketing and public relation (PR) services as well as news and media distribution. The Marketing theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Marketing Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Par Stock
To fully project Par Drugs' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Par Drugs And at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Par Drugs' income statement, its balance sheet, and the statement of cash flows.